Welcome to our dedicated page for Astellas Pharma news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on Astellas Pharma stock.
News for ASTELLAS PHARMA UNSP/ (ALPMY) centers on the activities of Astellas Pharma Inc., a global life sciences company active in medicinal and botanical manufacturing and pharmaceutical development. Company press releases highlight developments across oncology, ophthalmology, urology, immunology and women’s health, as well as collaborations with partners, startups and academic institutions.
Investors and observers following ALPMY-related news will see frequent oncology updates. Recent items include long-term overall survival data for XTANDI (enzalutamide) in metastatic hormone-sensitive prostate cancer from the ARCHES and ENZAMET trials, and new analyses of PADCEV (enfortumab vedotin) in locally advanced or metastatic urothelial carcinoma. Astellas also announces its broader oncology presence at major meetings such as the ASCO Annual Meeting, where it presents multiple abstracts on approved therapies and pipeline programs, including a selective protein degrader targeting KRAS G12D.
Ophthalmology news features IZERVAY (avacincaptad pegol intravitreal solution), a C5 inhibitor for geographic atrophy secondary to age-related macular degeneration in the United States. Astellas reports new data from the GATHER Phase 3 studies and related analyses at ophthalmology congresses, covering biomarkers, disease mechanisms, patient experience and imaging-based structure–function relationships.
News flow also covers strategic partnerships and ecosystem-building initiatives. Examples include agreements with the Korea Institute of Startup and Entrepreneurship Development and Mitsubishi Research Institute to support drug-discovery startups in Korea and Japan, the Astellas Future Innovator Prize at MBC BioLabs for early-stage biotech companies, and a planned joint venture with YASKAWA Electric Corporation to develop a cell therapy manufacturing platform using the Maholo robot. Additional releases describe patient-centric campaigns such as Patient Advocacy Organization (PAO) Action Week and governance updates on nominees for the Board of Directors. Together, these news items provide a view into Astellas’ research focus, collaborations, patient engagement and corporate oversight relevant to ALPMY.
FAQ
What is the current stock price of Astellas Pharma (ALPMY)?
What is the market cap of Astellas Pharma (ALPMY)?
